Greenwich LifeSciences (GLSI) announced on Monday that its board has extended the period during which company executives, directors, and early investors are prohibited from selling their holdings until September 30, 2026.

The decision restricts the disposal of common stock for approximately 72 months after the initial public offering, unless the directors choose to alter the conditions, the company stated.

Any subsequent divestments of these securities after the new deadline will be managed through a volume-restricted plan, Greenwich said.

The firm is presently testing its GLSI-100 immunotherapy in a Phase 3 study for the treatment of breast cancer, it added.

Shares of the company were up by over 1% in recent Monday premarket activity.